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RNA Polymerase II (RNAP II) is an enzyme that catalyzes the synthesis of the 
majority of mRNA in eukaryotic cells, making it essential for the first step of gene 
expression and vital for survival.  The process of transcription occurs in every living 
cell, which makes understanding its mechansims all the more important.  RNAP II 
consists of 12 subunits, of which Rpb1 is the largest.  The Rpb1 subunit participates in 
RNA elongation in the active site of the enzyme.  Residues located in Rpb1 have also 
been suggested to have a potential role in backtracking and arrest.3  Backtracking occurs 
when RNAP II moves backward along the DNA and the 3’ end of the RNA becomes 
dislodged from the active site.  The backtracked RNA, which extrudes from the pore of 
the enzyme, binds to nearby residues creating a “backtrack site.”3  If the polymerase has 
not backtracked extensively, these interactions will be weak and RNAP II can 
spontaneously resume transcription.  However, if the polymerase has backtracked 
extensively, forward elongation stops and RNAP II arrests.3  This study had two 
primary focuses: creating mutations in budding yeast (Saccharomyces cerevisiae) Rpb1 
residues that interact with backtracked RNA and characterizing Rpb1 mutants via 
sensitivity tests involving mycophenolic acid and canavanine to determine the speed 
and accuracy of the mutants respectively.  Creating and characterizing these mutant 
polymerases will give insight into what happens when the backtrack site is destabilized, 
which in turn could elucidate why backtrack site residues have been conserved in the 
first place.   
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Introduction 
There are an estimated 37.2 trillion cells in the human body.1  Within the 
nucleus of each of those cells, the process of transcription occurs to ensure that the cell 
can make the proteins it needs for survival.  Transcription is the process of creating an 
RNA transcript from a DNA template.  After the RNA transcript is made, another 
process called translation directs the synthesis of the protein, as shown in Figure 1.   
 
Figure 1: The central dogma of molecular biology.  Image source: 
https://defensedefumer.wordpress.com/2009/11/13/huh-what-what-is-molecular-biology/ 
RNA polymerases are the enzymes responsible for catalyzing the synthesis of RNA in 
the cell.  In the nucleus of eukaryotic cells, there are three primary classes of RNA 
polymerases that synthesize different types of RNA.2  RNA polymerase II (RNAP II) 
synthesizes messenger RNA (mRNA), small nuclear RNA (snRNA), and microRNA.  
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Because the majority of what RNAP II produces is mRNA, this study focused on the 
transcription of mRNA and the phenomenon of backtracking in that process. 
Backtracking occurs when RNAP II moves backward along the DNA template 
and the 3’ end of the RNA becomes dislodged from the active site.3  To pick an 
arbitrary direction, if RNAP II is moving from left to right, then backtracking occurs 
when the enzyme moves from right to left.  Movement of the polymerase is best 
described by three possible states of the elongation complex.  During active 
transcription, the transcription elongation complex (TEC) can be in one of two states at 
any given time: pre-translocated and post-translocated.4  In the pre-translocated state, 
RNAP II has just added a nucleotide to the RNA transcript, and in the post-translocated 
state, it has moved along the DNA template and awaits the addition of another 
nucleotide.4  There is a third state called reverse translocated in which the enzyme has 
moved backward along the DNA template, and this state results from backtracking.  In 
this state, the TEC changes conformation, and this causes the nascent RNA transcript to 
extrude from the enzyme and elongation to come to a stop,3 as shown in Figure 2. 
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Figure 2: RNAP II in two of its possible states.3   
The top panel depicts RNAP II in the pre-translocated state.  The middle panel shows 
the polymerase pausing before either continuing to transcribe or backtracking.  The 
bottom panel shows RNAP II in the reverse translocated state,4 after it has undergone 
backtracking.3 
   
If the polymerase has not backtracked extensively, interactions between residues of the 
polymerase and the backtracked RNA will be weak and RNAP II can spontaneously 
resume transcription.  However, if the polymerase has backtracked extensively, forward 
elongation stops and RNAP II arrests.3  More research is currently being done to 
understand this phenomenon and the role it plays in the transcription cycle.    
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This study was done in Saccharomyces cerevisiae, or budding yeast.  Budding 
yeast is an ideal model organism for studying backtracking because Saccharomyces 
cerevisiae has a fast growing rate, is easily genetically manipulated, is well studied, and 
has many highly conserved sequences in the protein-encoding portions of its genome.  
As much as 53% identity has been found in yeast and human RNAP II sequences.5  A 
study done by Shpakovski et al. showed that when genes encoding four subunits of 
human RNAP II were cloned into yeast, the yeast RNAP II was completely functional.6  
The conserved residues are also distributed all over the polymerase, making study in 
RNAP II in one organism fairly predictive of the results of the same study in another 
species.5   
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Existing Literature 
What is the Purpose of Backtracking? 
The fidelity with which DNA is transcribed into RNA is crucial to making 
functional proteins that are necessary for life.  Because of the need for high accuracy, 
enzymes such as RNAP II have proofreading mechanisms to keep transcriptional error 
rates as low as 10-5 per nucleotide, or less than one error per protein-encoding 
transcript.4  Backtracking behavior of the polymerase is thought to play a part in the 
proofreading activity of the enzyme.  Proofreading requires that the enzyme has a 
mechanism for determining when an incorrect nucleotide has been added to the 
transcript.  It is known that a related enzyme, DNA polymerase, has such a mechanism 
in that misincorporated nucleotides slow down the rate of addition of the next 
nucleotide.7  A study done in 1998 by Thomas et al. showed that RNAP II shared a 
similar mechanism and that nucleotide addition after a misincorporated nucleotide 
occurred 15-20 times slower than after addition of the correct nucleotide.7  The 
explanation of backtracking as proofreading activity seems to be logical if we only 
consider non-extensive backtracking (1-2 nucleotides), because in this case, the 
polymerase can spontaneously resume transcription.8  The true question surrounding the 
purpose of backtracking arises when we consider extensive backtracking (3 or more 
nucleotides).  With the 3’ end of the RNA transcript extruding, RNAP II cannot resume 
transcription right away.8  This occurs because interactions between the enzyme and the 
backtracked RNA stabilize the complex and lead to transcriptional arrest,3 as shown 
in Figure 3. 
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Figure 3: From the top panel down: non-extensive backtracking and extensive 
backtracking and arrest.3 
Cheung and Cramer proposed that the stability of the arrested complex comes 
specifically from the binding of at least eight nucleotides of backtracked RNA to the 
Rpb1 and Rpb2 subunits of RNAP II, as shown in Figure 4.  My research aims to 
determine what happens when the residues that are suggested to contact the backtracked 
RNA are mutated.   
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Figure 4: Backtracked RNA (shown in red) and the proposed contacts it makes with RNAP II.3  The 
residues of the polymerase that I wanted to mutate are designated by black arrows. 
Each of the RNAP II residues suggested to contact backtracked RNA are located in 
Rpb1 or Rpb2, as those subunits make up the active site of the enzyme.  This is 
illustrated in Figure 5.  We chose to mutate these specific residues because they are 
suggested to directly contact backtracked RNA and thus have a direct, stabilizing effect 
on the backtrack site.   
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Figure 5: Structure of RNAP II.5 
The left panel shows a ribbon diagram of the subunits of yeast RNAP II in relation to 
each other and to template DNA from a top view.  The right panel describes the colors 
used to designate each subunit.  Rpb1 (gray) and Rpb2 (brown) residues are suggested 
to contact backtracked RNA. 
What Causes Backtracking? 
Backtracking and transcriptional arrest have several suggested causes, including 
a scarcity of nucleotides, lack of RNAP II reactivation factors (in mutants), obstacles in 
DNA such as nucleosomes, DNA lesions,9 and misincorporated nucleotides.10  Several 
experiments were done using drugs that provoked NTP depletion such as 6-azauracil 
and mycophenolic acid in order to induce a scarcity of nucleotides.  This resulted in a 
lower elongation rate and processivity of RNAP II in vivo, which is correlated with an 
increase in the frequency of arrest.9  When these drugs were tested in combination with 
yeast mutants that lacked RNAP II reactivation factors, the result was even more 
pronounced.9  Nucleosomes have also been shown to promote backtracking in vitro 
because they create a physical hindrance for the transcribing complex.9  DNA damage is 
suggested to cause arrest that is often irreversible and can only be resolved by 
degradation of the polymerase.9  Specific sequences of  undamaged DNA have also 
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been found to increase the incidence of backtracking and arrest.  Pyrimidine-rich tracks 
in the non-template strand in particular induce RNAP II arrest.9  This was suggested 
to occur because the high proportion of A-U base pairs made for a weaker DNA-RNA 
hybrid, and this makes sense because there is a strong preference for pyrimidines in the 
interactions between backtracked RNA and the “backtrack site.”9  Finally, experiments 
have been done in which artificially induced misincorporation of nucleotides resulted in 
an increase in the incidence of backtracking.10 
How is Backtracking Resolved? 
Backtracking and subsequent transcriptional arrest are not permanent or there 
would be no transcription of the gene, no mature RNA from which to synthesize the 
protein, and ultimately no protein made.  This would lead to cell death in most cases.  
The cell has developed three ways to overcome arrest: spontaneous continuation of 
elongation, RNA cleavage, and degradation of the arrested RNAP II.9   As previously 
mentioned, if backtracking is not extensive RNAP II can spontaneously resume forward 
elongation.  Because pausing and non-extensive backtracking is thought to be a fairly 
common occurrence,9 this mechanism is likely the most utilized out of the three in vivo.  
However, when the polymerase cannot spontaneously resume transcription, one 
of the other ways it recovers from arrest is the cleavage of backtracked RNA, which 
creates a new 3’ end of the RNA transcript.9  This can be achieved in a number of ways, 
one of which includes the recruitment of transcription factor SII (TFIIS) to the site to 
cleave the backtracked RNA, as illustrated in Figure 6. 
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Figure 6: TFIIS cleavage of backtracked RNA.3 
X-ray crystallography data from Cheung and Cramer has indicated that the mechanism 
for this cleavage involves TFIIS weakening the interactions between RNAP II and the 
backtracked RNA and subsequently displacing the backtracked RNA by competitive 
binding to the backtrack site.3  However, even in the absence of TFIIS the cell can still 
induce cleavage and resume transcription.  RNAP II has weak intrinsic nuclease 
activity which is greatly enhanced by TFIIS.11  Although it is still not entirely clear 
which subunits of RNAP II participate in this intrinsic nuclease activity, a small subunit 
called Rpb9 (see Figure 5) is thought to play a role.  In the absence of a functional 
Rpb9, RNAP II was less able to induce cleavage even in the presence of TFIIS and it 
generated different cleavage products.11    
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An alternative mechanism for the continuation of transcription without cleavage 
is mediated by a protein complex called Ccr4-Not.9  This complex has been found to 
localize where mRNA degradation takes place in the cell, so it could be interacting with 
the extruding RNA transcript to degrade it and allow the polymerase to continue to 
elongate.9  If all other mechanisms of reactivation fail, the cell tags the largest subunit of 
RNAP II, Rpb1, for degradation9 and this has been termed the “last resort” pathway.12  
The process of tagging Rpb1 for degradation occurs via the ubiquitylation 
pathway and was originally identified as a response to DNA damage serious enough to 
interrupt transcription.12  However, later studies have shown that other conditions can 
induce the ubiquitylation response as well.  Some of these conditions include treatment 
with the transcriptional toxin α-amantin and specific mutations of the TFIIS gene.12 
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Research Question 
My research centered around a broad question that can be narrowed down as 
illustrated in Figure 7. 
 
 
 
 
 
 
 
 
 
 
Figure 7: Guiding research questions. 
The existing literature still cannot answer what the exact function of extensive 
backtracking is.  While there has been comprehensive work done on what this 
mechanism might physically look like, what causes it, and what can resolve it, its 
benefit to RNAP II and the cell overall is still largely unknown.  The fact that these 
residues have been conserved and that a backtrack site exists indicates that extensive 
backtracking must provide a benefit to RNAP II and the cell, otherwise those residues 
would likely have mutated and the behavior would have disappeared.  Alternatively, the 
backtrack site could exist in order to prevent the polymerase from moving further 
backwards along the DNA.  In order to find out why these residues may have been 
conserved, it must first be determined what they are contributing to the stability of the 
What is the function of extensive backtracking? 
Why have residues of the backtrack site been conserved? 
What happens when the backtrack site is destabilized? 
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backtrack site and if they are necessary for viability.  A common way to do this is to 
mutate these residues and run phenotypic tests to characterize the behavior of the 
mutant polymerases.  This study involved the characterization of RNAP II mutants 
using phenotypic tests and the creation of new mutants.    
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Methods 
Creation of Mutants 
The first backtracked nucleotide is suggested to make contact with three RNAP 
II residues: T827 (Rpb1), E529 (Rpb2), and Y769 (Rpb2).3  The next backtracked 
nucleotide contacts Rpb1 residues Q1078 and T1080, both of which are located in a part 
of the enzyme called the trigger loop.  Another backtracked nucleotide, located three 
nucleotides away, binds in a pocket, contacting two Rpb1 residues, R726 and I756 (see 
Figure 4).3  This study focused on creating point mutations in four of those residues 
based on these proposed contacts: T827, Q1078, T1080, and R726.  The point 
mutations would cause the DNA at these positions to code for different amino acids 
which should not be able to bind the same way to backtracked RNA.  I will discuss the 
methods used to create new RNAP II mutants before I discuss the characterization of 
existing mutants. 
The creation of mutations in the Rpb1 subunit of RNAP II consists of three 
phases: site-directed mutagenesis, introduction of mutation into the pRP114 vector, and 
recovery of the mutated yeast plasmid.*  Site-directed mutagenesis involves PCR using 
an appropriate TOPO vector and mutagenic primers, as illustrated in Figure 8.  The 
TOPO vector was used because it contains part of the Rpb1 gene and is a small plasmid, 
making it easier to work with in PCR.  If the PCR was successful, the PCR product was 
digested with Dpn1.  The digested PCR product was then introduced into Escherichia 
coli (E. coli) via a bacterial transformation.  If colonies grew, bacterial minipreps were 
                                                        
* Detailed protocols can be found in Supplementary Information. 
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performed to extract the DNA from the bacteria and the DNA was sent for sequencing.  
Once the sequencing results confirmed that the mutation was present in the TOPO 
vector, it could move into the introduction into pRP114 phase.  
 
Figure 8: Site-directed mutagenesis and introduction of a mutation.  From left to right: 
bacterial plasmid containing a portion of the Rpb1 gene (blue with pink) and chemically 
synthesized oligonucleotide primer containing the desired mutation (pink) are 
combined in a polymerase chain reaction (PCR).  The primer binds to the template 
DNA, and DNA polymerase extends from the primer to make a plasmid containing the 
mutation. 
pRP114 is a yeast plasmid that is used to interchange parts of plasmids via homologous 
recombination.13  pRP114 has a complete Rpb1 gene, which allows the mutated 
fragment to bind where it has complementary sequence after pRP114 has been digested, 
and in this way the mutation can be taken out of the bacterial vector and introduced to 
the yeast vector, as shown in Figure 9.  
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Figure 9: Homologous recombination and incorporation of mutated DNA into yeast.  
The TOPO vector PCR product with the desired mutation (blue) and the cut yeast 
plasmid (yellow) are combined in a high efficiency yeast transformation in order to 
facilitate homologous recombination.  
The first steps in this phase include digesting pRP114 with appropriate restriction 
enzymes and running it on a gel to isolate the cut plasmid.  Gel extraction was used to 
isolate the cut plasmid from the gel.  Simultaneously, the TOPO vector with the desired 
mutation was used in another PCR reaction to amplify the mutation.  The cut yeast 
plasmid and TOPO vector PCR product were then combined in a high efficiency 
transformation with yeast competent cells in order to allow homologous recombination 
and incorporation of the mutated fragment into the yeast plasmid.  The yeast strain used 
for Rpb1 mutants was DHY 464.  This strain of yeast has the Rpb1 gene deleted from 
the chromosome so that any copies of the gene present would be on plasmids, which are 
much easier to keep or remove via plating on selective media.  These transformations 
were plated on SD-Leu to select for colonies that had incorporated the mutated plasmid, 
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because pRP114 contains the Leu2 gene.  As a result, only the yeast colonies that took 
up the mutated plasmid would survive on media without leucine. 
If colonies grew from this transformation, they proceeded into the recovery 
phase.  Colonies were streaked onto 5-FOA plates in order to select against the Ura3 
gene, which also had a wild type copy of the Rpb1 gene on the same plasmid.  The loss 
of this plasmid meant that colonies that grew on these plates theoretically only had one 
copy of the Rpb1 gene now, and it contained the mutation that was created in a previous 
step.  The yeast DNA was isolated using a yeast miniprep protocol and transformed into 
E. coli using DH5-α competent cells.  If colonies grew, bacterial minipreps were done 
and the DNA was sent for sequencing to confirm the presence of the mutation.   
Alternative Methods 
A large part of my thesis project has involved troubleshooting PCRs, and as a 
result it was decided that I should investigate alternative methods for making mutants.  
The proposed changes included introducing two new restriction sites, or places where 
an enzyme could cut the DNA.  I used site-directed mutagenesis once again using the 
same Rpb1 TOPO vector to create two point mutations which would in turn create the 
restriction sites.  These restriction sites were strategically placed around the mutations 
we wanted to make.  This means that in the future, we can use the two corresponding 
restriction enzymes (DraIII and BamHI) to cut the plasmid and order an 
oligonucleotide with the desired mutation to incorporate into the cut plasmid.  The 
creation of this strain with extra restriction sites will allow us to skip several steps 
normally involved in site-directed mutagenesis and cloning, including the time-
consuming mutagenic PCR. 
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Characterization of Mutants 
Another focus of this project was to characterize seven existing mutants using 
several phenotypic tests.  The seven existing RNAP II mutants characterized were 
R726S, A729V, V747I, T834A, D826N, M1079T, and A1076T.∗  These mutations 
were obtained in screens testing for mutant phenotypes, including the blue/white screen 
and mycophenolic acid sensitivity test.  After the mutant phenotypes had been 
identified, we wanted to characterize them further using the mycophenolic acid test 
again as well as a canavanine sensitivity test.  The results from these tests taken with the 
results from the blue/white screen give insight into how these mutants behave 
differently than wild type RNAP II in terms of their speed, accuracy, and ability to 
recognize termination signals.  We chose to further characterize these mutants because 
they are in the immediate vicinity of the residues suggested to contact backtracked RNA 
that we hoped to mutate.  These residues do not directly contact the backtracked RNA, 
but are likely still important for the stabilization of the backtrack site, and it would be 
useful to know if they share a common mutant phenotype.   
Blue/white screen 
The blue/white screen tests RNAP II mutants for termination phenotypes.  A 
reporter plasmid, pL101Btrp, contains the E. coli LacZ open reading frame under 
control of the Gal10 promoter.14  This promoter is inducible in the presence of 
galactose.  A polyadenylation signal is located in an intron upstream of the open 
                                                        
∗ The naming convention for RNAP II residues is as follows: the first letter is the one-letter abbreviation 
for the original amino acid and the number is the position of that amino acid in the polypeptide.  The 
second letter is only added if a mutation has been made, and it is the one-letter abbreviation of the new 
amino acid at that position. 
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reading frame of LacZ, which makes the time window for cleavage much shorter, 
because it must occur before the intron is removed by splicing.14  If the 
polyadenylation signal is not recognized, RNAP II fails to terminate and the LacZ gene 
is transcribed.15  Plated on media with galactose, the transcription and subsequent 
translation of the LacZ gene causes the yeast colonies to turn blue when exposed to X-
Gal.  If the polyadenylation signal is recognized, RNAP II will terminate and the LacZ 
gene product will not be made, leaving the colonies white.  Yeast with wild type RNAP 
II and this reporter construct turn light blue due to random chance that splicing occurred 
before the polyadenylation signal was recognized.14  This means that RNAP II mutants 
that have a blue phenotype (such as A729V below) have termination defects that 
prevent them from recognizing termination signals.  Table 1 summarizes data already 
collected about the mutants from the blue/white screen. 
Mutant Results of 
Blue/White 
Screen 
R726S W 
A729V B 
V747I W 
D826N W 
T834A W 
A1076T wt 
M1079T wt 
Table 1: Rpb1 mutations and results of the blue/white screen.  B denotes a blue 
phenotype, W denotes a white phenotype, and wt denotes a wild type phenotype. 
Mutant phenotypes in the blue/white screen are also correlated with defects in 
elongation speed in-vitro.  The blue phenotype is associated with a faster-than-wild-type 
elongation rate, while white phenotypes are associated with both fast and slow 
elongating polymerases.  Based on previous unpublished data collected by the lab, it 
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appears that a combination of the white phenotype and fast elongation rate is correlated 
with backtracking defects. 
Mycophenolic acid 
Mycophenolic acid (MPA) is a competitive inhibitor of the enzyme IMP 
dehydrogenase (IMPDH).16  IMPDH is the rate-limiting enzyme in de novo guanine 
biosynthesis,16 and when it is inhibited, the cell experiences a shortage of GMP.  This 
creates an imbalance in NTPs available, which makes polymerases that already have 
trouble elongating especially sensitive.21  There are two start sites for transcription of 
the IMPDH gene, and wild type RNAP II can shift to the downstream start site when 
there is a shortage of GMP.21  The upstream start site for IMPDH is used when GMP is 
relatively abundant.21  Some RNAP II mutants are unable to make this shift or prefer 
one start site over the other.  This test is primarily used to determine whether RNAP II 
mutants with a white phenotype in the blue/white screen are fast or slow elongating 
polymerases.  Both fast and slow elongating polymerases have defects relative to wild 
type polymerases.  However, it has been hypothesized that gain-of-function mutants use 
the upstream start site and are associated with faster-than-wild-type elongation 
phenotypes while loss-of-function mutants use the downstream start site and are 
associated with slower-than-wild-type elongation phenotypes.21  This hypothesis could 
be incorrect, because data from our lab suggests that both fast and slow polymerases are 
sensitive to MPA.   
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Canavanine 
Rpb1 mutants were also characterized using a canavanine sensitivity test.  This 
tests the accuracy of mutant polymerases.  Canavanine is a compound that is 
structurally similar to the amino acid arginine but is toxic.  The CAN1 gene encodes an 
arginine transporter, and this transporter also imports canavanine into the cell, killing it.  
The strains in this study have a mutation in the CAN1 gene called CAN1-100, which is a 
nonsense mutation.  This mutation prevents expression of a functional arginine 
transporter, and as a result, cells plated on canavanine that read this gene correctly will 
survive.  Some RNAP II mutants make errors when transcribing, which can result in the 
production of a functional arginine transporter and when plated on canavanine, cell 
death.15  Decreased cell growth in this assay is associated with RNAP II mutants with 
higher rates of transcriptional infidelity.      
 
 
 
 
 22 
 
Results and Discussion 
Creation of Mutants 
Of the four Rpb1 mutations, one mutant was successfully created, which was 
T827A.  In this mutant RNAP II, the threonine side chain at position 827 was 
successfully mutated to code for an alanine residue (see Supplementary Information for 
Amino Acid Reference Table). As Table 2 shows, the troubleshooting process for the 
other mutations is ongoing. 
PCR Mutation DNA Polymerase Protocol Changes Results 
M7 R726H KOD 5.4 µL 100:1 RPB1 
TOPO 2 template DNA 
low molecular weight 
smear 
M8 R726H KOD Lowered Tm by 1°, 
65.3° 
Different DMSO 
low molecular weight 
smear 
M9 T827A KOD Lowered Tm by 1° successful 
M10 R726H KOD Lowered Tm by 2°, 
64.3° 
low molecular weight 
smear 
M11 Q1078H KOD 9 µL 100:1 RPB1 
TOPO 3 template DNA 
  
low molecular weight 
smear 
M12 T1080I KOD same as M11 low molecular weight 
smear 
M13 Q1078H KOD 1 µL undiluted template 
DNA 
low molecular weight 
smear 
M14 Q1078H KOD no DMSO low molecular weight 
smear 
M15 R726H KOD Annealing time 
increased to 30s 
Lowered Tm to 62.3° 
for first 7 cycles, then 
raised it to 66.3° for the 
next 13 
10:1 template DNA 
low molecular weight 
smear 
M16 R726H KOD 1 µL 10:1 template 
DNA 
Increased denaturation 
time to 30s 
Decreased Tm to 60° 
low molecular weight 
smear 
M17 Q1078H KOD 10:1 template DNA 
Decreased Tm to 60° 
low molecular weight 
smear 
M18 T1080I KOD same as M17 low molecular weight 
smear 
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M19 T827A KOD Denaturation and 
annealing time both 
increased to 30s 
low molecular weight 
smear 
M20 Q1078H Phusion none a long smear 
M21 Q1078H Phusion 1 µL of 100:1 RPB1 
TOPO 3 
Tm lowered to 54.3° for 
first 7 cycles and raised 
to 72° for last 18 
a long smear 
M22 Q1078H Phusion GC buffer instead of 
HF 
1 µL of Phusion 
3 min extension time 
no true bands or smears 
Table 2: PCR modifications to create Rpb1 mutants. 
In polymerase chain reactions (PCRs), there are three main steps: separation of 
the DNA strands, primer annealing to the separated strands, and extension of the 
primers by a DNA polymerase to create full length DNA.17   Theoretically the amount 
of DNA doubles after each cycle until later PCR cycles when there is more primer-
template than there is enzyme to extend it.17  DNA concentration plateaus at this phase 
and may even start to decrease.  Another reason for the decrease in DNA concentration 
is the formation of primer-dimer, which could be what was occurring when we saw low 
molecular weight smears.  However, it is not known whether the smear actually 
indicated primer dimer or unused primers.  Primer-dimer occurs when two primers 
anneal to each other rather than the template DNA and form a duplex.17  One study 
suggested that primer-dimer formation can be suppressed by adding nucleotides to the 
5’ ends of the primers.17  The extra nucleotides could possibly lower the chance that the 
primers would anneal to each other, making binding to the template DNA even more 
favorable.  Another technique suggested to prevent the formation of primer-dimer is 
increasing the temperatures used in the annealing step of the PCR.17   Figure 9 details 
other common problems and potential fixes for PCR reactions. 
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Figure 10: Possible explanations of and fixes for lack of PCR product.18 
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Site-directed mutagenesis via PCR is a complex procedure that can be influenced by a 
number of factors.  However, the creation of the mutant with two new restriction sites, 
called TOPO 2 B+D, will change the way that these mutant polymerases are made in 
the future.  With the additional DraIII and BamH1 restriction sites, the plasmid can be 
cut and an oligonucleotide with the desired mutations can be incorporated into the 
plasmid directly.  The restriction sites are strategically placed around the mutations we 
want to make, as illustrated in Figure 11.  As a result, site-directed mutagenesis via PCR 
can be skipped in its entirety, which will save time and allow us to move on to the next 
step: characterization of the Rpb1 mutants.  This will also allow us to create double 
mutants much more easily.  
 
Figure 11: Restriction sites in the new TOPO 2 B+D mutant. 
All of the Rpb1 residues proposed to contact the backtrack site (green), excluding the 
two trigger loop residues, are between the newly created DraIII site (yellow) and 
endogenous XbaI site (blue).  The BamHI site (yellow) will allow groups of mutations 
in this region to be combined more easily.  The blue bases in the DraIII and BamHI 
sites are the bases that were mutated to create those restriction sites. 
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Characterization of Mutants 
Mycophenolic Acid 
The results indicate that T834A and A729V grew better than most of the other 
Rpb1 mutants, and on the other end, A1076T and R726S grew much worse.  While each 
of these mutations is located in the same subunit of RNAP II, Rpb1, they are located in 
different subdomains.  Some of the subdomains thought to be involved in backtracking 
include the pore, funnel, bridge helix, and trigger loop, some of which are shown in 
Figure 12.  
 
Figure 12: RNAP II trigger loop and bridge helix and other subdomains proposed to 
interact with them or NTPs.19 
R726S, A729V, and V747I are located in the funnel subdomain.  D826N and the new 
mutant, T827A (not shown above), are found in the bridge helix, and T834A, A1076T, 
and M1079T are in the trigger loop.  This makes the results more difficult to interpret, 
because there is no apparent pattern associated with placement of the mutations and 
growth on MPA plates.  Both the funnel and the trigger loop had mutations that showed 
very good growth and fairly poor growth.  It is important to note that A729V was the 
only mutant which showed a blue phenotype in the blue/white screen, indicating it 
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could have termination defects.  The other mutants tested had white phenotypes with the 
exception of M1079T and A1076T, which had wild-type phenotypes in that assay.  The 
MPA test allowed us to determine the ability of the mutant polymerases to shift to the 
downstream start site for transcription of the IMPDH gene.  Poor growth indicates less 
of an ability to shift to the downstream start site and is correlated with a faster-than-
wild-type elongating polymerase with elongation defects.  Figure 13 shows the results 
of the dilution series for each mutant plated on MPA. 
 
Figure 13: Results of the MPA sensitivity test.  This shows that T834A > A729V > 
M1079T  = V747I > D826N > A1076T  = R726S. 
These results agree with previous MPA tests done in the lab, because M1079T, 
A1076T, and R726S all grew fairly poorly.  However, because V747I and D826N had 
wild type growth in previous assays, it would be worthwhile to do this test again.  While 
R726S 
T834A 
D826N 
V747I 
A729V 
A1076T 
M1079T 
464 
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it is still unclear how mutations in different subdomains affect the ability of RNAP II to 
switch start sites, many studies have focused on the trigger loop in particular.  It has 
been shown that the trigger loop regulates basic elongation rate as well as participates in 
NTP substrate selection and mismatch recognition.20  
As a result, the trigger loop is a major contributor to transcriptional fidelity, and 
mutations in trigger loop residues can have varying effects.19  One study suggested that 
RNAP II trigger loop mutants increase activity for all substrates, and even more so for 
mismatched NTPs, thereby reducing selectivity.19  Conversely, mutations in the bridge 
helix have been shown to increase RNAP II activity in a way that promotes 
translocation or catalysis.19  In summary, these results suggest that mutations in residues 
that form the backtrack site have a visible effect on RNAP II.  Some mutants grew 
better, some mutants grew worse, but none of the mutations caused a lethal phenotype.  
However, the strain that grew the worst was actually the control.  I also plated DHY 
464, which was the parent yeast strain for these mutations.  RNAP II in this strain does 
not have mutations in Rpb1 residues and is used for comparison against the Rpb1 
mutants.  Theoretically 464 should model wild-type growth, and because it didn’t, this 
experiment should be repeated before coming to any conclusions. 
Canavanine 
There was no growth of any of the mutants on canavanine plates, which could 
suggest that the inaccuracy with which the CAN1 gene was transcribed restored the 
functional mRNA, leading to a functional arginine transporter.  With a functional 
arginine transporter, canavanine would be imported into the cell, which causes cell 
death.  This would agree with data from previous work with these mutants, because 
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R726S, A729V, T834A, and M1079T all showed decreased growth in canavanine 
sensitivity tests.  Each showed signs of sickness, or decreased growth, in varying levels 
of severity.  However, V747I, D826N, and A1076T all showed growth similar to wild-
type in previous tests, which does not agree with my results.  My results could also be 
confounded by the failure of the controls and/or contamination of the plates.  RNAP II 
mutants were plated on SD-Arg as a control, and there was no observed growth on these 
plates either.  This media should not have had an effect on the growth of the mutants.  I 
also plated DHY 464, which was the parent yeast strain for these mutations.  RNAP II 
in this strain does not have mutations in Rpb1 residues and is used for comparison 
against the Rpb1 mutants.  DHY 464 did not grow on canavanine or SD-Arg.  My 
results could indicate that these mutations make the yeast more “sick” than previously 
thought, but these experiments should be repeated before coming to any conclusions.     
 30 
 
Future Directions 
These experiments showed that creating point mutations in various subdomains 
of the Rpb1 subunit of RNAP II has an effect on the ability of the polymerase to 
recognize termination signals, shift to downstream start sites, and the speed of 
elongation.  The mutations may also have an effect on the accuracy with which the 
polymerase transcribes genes, although there is not yet enough data to come to a 
conclusion.  In the future these experiments should be replicated in order to determine if 
there is any type of pattern in the phenotypes seen and the location of the mutations in 
Rpb1 subdomains.  Next steps should include combining point mutations and 
effectively obliterating the backtrack site to see if it has more of an effect on the 
phenotype of the mutant polymerases.  The ability to make double mutants will be made 
much easier by the creation of the TOPO 2 B+D mutant with the BamHI and DraIII 
restriction sites.  The Rpb1 mutations should also be introduced into strains of yeast that 
have Rpb9 or TFIIS deletions.  Rpb9 is a small subunit thought to play a role in the 
intrinsic nuclease activity of the polymerase, and it would be interesting to combine its 
deletion with the destabilization of the backtrack site.  The same idea applies to the 
TFIIS deletion strain, because TFIIS is the transcription factor that cleaves backtracked 
RNA and rescues arrested polymerases.  In conclusion, there is still much work to be 
done before we understand why backtrack site residues have been conserved and what 
the function of extensive backtracking truly is.         
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Glossary 
amplify – to increase in number 
 
anneal – the process by which nucleic acids create hydrogen bonds and form a pair of 
DNA molecules  
 
cloning – the process used to assemble recombinant DNA and direct its replication in 
host organisms 
 
competent – the ability of a cell to take up exogenous genetic material 
 
conserved – a sequence in DNA or a protein that has remained essentially unchanged 
even between different species and throughout evolution 
 
enzyme – proteins that are capable of catalyzing specific biochemical reactions 
 
fidelity – accuracy 
 
homologous recombination – exchange of genetic material between two similar 
molecules of DNA 
 
identity – identical sequence 
 
intron – an sequence of DNA that does not encode for RNA 
 
lesions – sites of DNA damage 
 
microRNA – small RNA that does not code for protein, functions in post-transcriptional 
gene regulation 
 
mRNA – RNA that conveys genetic information to the ribosome, proteins are coded 
from this type of RNA 
 
nascent – newly synthesized 
 
non-template strand – the strand of DNA that is not being actively transcribed into RNA 
 
NTP (nucleotide) – nucleotide triphosphate, also called nucleotides, which are 
essentially the building blocks for DNA and RNA (A,T, C, G, and U) 
 
nuclease activity – enzyme activity that cleaves bonds between nucleic acids 
 
nucleosomes – basic unit of DNA packaging in eukaryotes, consisting of DNA wrapped 
around a protein core 
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open reading frame – the portion of a gene that has the potential to be translated 
 
PCR – a procedure used to amplify copies of DNA or introduce mutations 
 
phenotype – the result of an organism’s genotype that is observable 
 
polyadenylation – addition of the poly(A) tail to mRNA 
 
primer – a strand of nucleic acid that serves as a starting point for DNA synthesis 
 
processivity – the number of nucleotides a polymerase can incorporate into the 
transcript before it releases the template 
 
promoter – a region of DNA that initiates transcription of a particular gene 
 
pyrimidine – any of the nitrogenous bases U, C, or T, which are components of nucleic 
acids 
 
reporter – a gene that is attached to a gene of interest so that it is easily assayed 
 
residue – a single amino acid in a protein 
 
restriction enzyme – an enzyme that catalyzes the cleavage of DNA 
 
restriction site – the site in DNA at which restriction enzymes cleave nucleotides by 
hydrolyzing the phosphodiester bond 
 
snRNA – small RNA that does not code for protein, functions in RNA processing 
 
substrate – material or substance on which an enzyme acts 
 
TOPO – a vector used for cloning 
 
transformation – genetic alteration via direct uptake of exogenous genetic material 
 
transcriptional arrest – when the process of transcription can no longer occur and a full 
transcript will not be made 
 
ubiquitylation – a process of protein tagging that marks other proteins for degradation 
 
wild type – a strain, gene, or characteristic that is predominant in nature 
 
 
5-FOA – 5-fluoroorotic acid, used in yeast genetics to select for absence of Ura3 gene
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Supplementary Information 
Amino Acid Reference Table 
Image source: Cojocari, D. (2010). Twenty-one amino acids. [Illustration]. University 
of Toronto. Retrieved from https://en.wikipedia.org/wiki/Proteinogenic_amino_acid. 
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Protocols  
Quick-Change PCR using KOD Hot-Start Polymerase 
Combine the following reagents in a PCR tube to make a 50 µL total reaction. 
Reagent Volume (µL) 
H2O 29.5 
10X Buffer 5 
25 mM MgSO4 3 
2 mM dNTPs 5 
10 µM Forward 
primer 
1.5 
10 µM Reverse 
primer 
1.5 
Template DNA 1 
100% DMSO 2.5 
KOD Hot-Start 
Polymerase 
1 
 
The volume of template DNA may vary depending on the concentration of the template 
DNA.  10-20 ng is sufficient for this reaction, so a dilution may be required.  More 
water is added if less than 1 µL of DNA is used.  The reaction is then placed in the 
Thermocycler, where the following protocol is used (in °C): 
1) 95°, 2 min. 
2) 95°, 20 s 
3) Tm of the primers, 10 s 
4) 70°, 3 min. 
5) Repeat steps 2-4 for 20 cycles 
 
If the PCR was successful (as determined by running the PCR product on a 1% 
agarose gel), then proceed to the Dpn1 digest.  For the Dpn1 digest, add 2 µL of Dpn1 
to the PCR product and incubate at 37°C for 10 minutes. 
Bacterial Transformation using XL2-Blue E. coli Competent Cells 
This transformation was used in the creation of the T827A mutant.   
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Combine 20 µL of PCR product and 100 µL of XL2-Blue competent cells and set on ice 
for 10 minutes.  Heat shock at 45°C for 1 minute and then put on ice for 1 minute.  Add 
800 µL of SOC media and incubate at 37°C for 1 hour.  Plate onto LB + AMP and 
incubate at 37°C overnight. 
Bacterial Transformation using TG1 E. coli Competent Cells 
This transformation was used in the creation of TOPO 2 B+D.   
Combine 100 µL of TG1 competent cells, 30 µL of sterile water, 20 µL of 5X KCM, 
and 20 µL of PCR product.  Incubate on ice for 30 minutes.  Heat shock at 42° C for 90 
seconds, and put on ice.  Plate on LB + AMP and incubate at 37°C overnight. 
Bacterial Miniprep 
A culture must be started the day before this protocol is performed.  A standard 3 mL 
culture is made by combining 3 mL of LB broth with 4 µL AMP/1 mL of LB broth (for 
a total of 12 µL of AMP).  Incubate overnight at 37°C with shaking.   
After the culture has grown to saturation, the cells can be pelleted in Eppendorf tubes 
and then proceed to the following steps: 
1) Resuspend in 250 µL of P1 solution and vortex 
2) Add 250 µL of P2 and invert to mix 
3) Add 350 µL of N3 and invert to mix 
4) Centrifuge at 13,000 rpm for 10 minutes 
5) Pour liquid into spin columns 
6) Centrifuge for 1 minute, discard flowthrough 
7) Add 500 µL of PB to column, centrifuge, and discard flowthrough 
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8) Add 750 µL of PE to column, centrifuge, and discard flowthrough 
9) Centrifuge again and discard flowthrough   
10) Transfer column to an Eppendorf tube 
11) Add 50 µL of EB to center of column 
12) Wait for 1 minute, centrifuge for 1 minute 
13) Keep flowthrough and measure the DNA concentration on a spectrophotometer 
pRP114 Enzyme Digest 
This digest was specific to the yeast plasmid used in these experiments, pRP114. 
Reagents Volume (µL) 
DNA 4.5 
1X FD buffer 2 
EagI restriction enzyme 1 
XbaI restriction enzyme 1 
Sterile water 11.5 
 
Put in thermocycler and hold at 37°C for 20 minutes.  Run the product on a 1% agarose 
gel.   
Gel Extraction 
Isolate the cut plasmid and cut it from the gel.  Determine the mass of the gel fragments 
and proceed to the following steps: 
1) Use 3 equivalents of QG buffer for every equivalent of gel (1 µL/1 mg of gel) 
2) Incubate ate 65°C until gel is completely dissolved, vortexing every 2.5 minutes 
3) Run through gel column and centrifuge for 1 minute 
High Efficiency Yeast Transformation 
Five days beforehand, grow the yeast strain you wish to use on YEPD for 2-3 days at 
30°C (I used DHY 464).  Start a 2 mL culture from one of the colonies in YEPD the day 
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before and let it incubate overnight at 30°C with shaking.  Add 700 µL of saturated 
culture to 10 mL of fresh media.  Grow to OD600 0.7-0.8 at 30°C.  Once the sample has 
reached the desired OD600, pellet cells at 7000 rpm.  Resuspend in 300 µL of sterile 
water and transfer samples to Eppendorf tubes.  Pellet the cells.  Resuspend in 180 µL 
of LiAcTE media.  Incubated with rotating for 20 minutes.  In another tube, combine 2 
µL of PCR product, 100 ng of digested yeast plasmid, and 300 µL of PEGLiAcTE 
solution.  Add 5 µL of 2.5 mg/mL boiled ssDNA.  Add 50 µL of cells from the culture 
to this mixture, and incubate at 30°C for 30 minutes on a rotator.  Heat shock at 42°C 
for 20 minutes.  Pellet cells and resuspend in 200 µL of sterile water.  Plate onto 
selective media (SD-Leu in my case) and allow growth for 2-3 days at 30°C. 
High Efficiency Yeast Transformation using Competent Cells 
Thaw 1 aliquot of competent cells on ice for 10 minutes from the -80°C freezer.  Add 
10 µL of 2.5 mg/mL boiled ssDNA, 2 µL of PRC fragment product, and 100 ng of 
digested plasmid DNA.  Add two volumes of 50% PEG3350 and incubate at 30°C for 30 
minutes.  Heat shock at 42°C for 15 minutes.  Pellet cells and resuspend in 1 mL of 
freshly made SOS media.  Incubate at 30°C for 1 hour.  Pellet cells and resuspend in 
200 µL of sterile water.  Plate onto selective media (I used SD-Leu) and allow growth 
for 2-3 days at 30°C. 
5-FOA Plates 
Use 0.1 g 5-FOA/100 mL agar for four plates.  Melt SD-bottom agar.  Add 10X amino 
acids to agar in sterile Erlenmeyer flask.  Spray stir bar with ethanol and briefly flame 
it.  Add flamed stir bar to flask.  Add 5-FOA and stir for 5 minutes.  Pour plates. 
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Yeast Miniprep 
Colonies from the 5-FOA plates should be restreaked onto SD-Leu, and a colony from 
the SD-Leu plate should be used to start a culture to prepare for the miniprep.  Proceed 
to the following steps: 
1) Pellet cells in Eppendorf tubes 
2) Resuspend in 250 µL of zymolase, BMA, and EDTA mix and vortex 
3) Incubate for 90 minutes at 37°C 
4) Add 50 µL of miniprep mix, vortex 
5) Incubate at 65°C for 30 minutes 
6) Add 63 µL of 5M KOAc, invert to mix 
7) Put on ice for 30 minutes 
8) Centrifuge at 13,000 rpm for 10 minutes 
9) Transfer supernatant to new tube 
10) Add 720 µL of ethanol, invert to mix 
11) Centrifuge for 10 minutes 
12) Dry pellet using desiccator for 10-15 minutes 
13) Resuspend in 50 µL of TE 
14) Store at -20°C 
Bacterial Transformation using DH5-α E. coli Competent Cells     
Aliquots of DH5-α cells should be thawed from the -80°C freezer for 10 minutes, and 
proceed to the following steps: 
1) Add 1 mL of cold 0.1M CaCl2 to each 50 µL aliquot of DH5-α cells and mix 
well 
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2) Add 250 µL of cells to 1.5 mL of yeast miniprep DNA in a small culture tube 
3) Incubate on ice for 1 hour 
4) Heat shock at 37°C for 2 minutes 
5) Add 1.5 mL of LB broth and incubate for 1 hour at 37°C 
6) Transfer cells to Eppendorf tubes and pellet 
7) Remove all but 200 µL of broth 
8) Resuspend cells and plate on LB + 4X AMP 
9) Incubate overnight at 37°C   
Yeast Strain “Magic” Transformation 
The yeast strain that you wish to use should be grown in an overnight culture in YEPD.  
Once culture is saturated, proceed to the following steps: 
1) Pellet 250 µL of saturated culture 
2) Resuspend in 86 µL of freshly made “magic mix,” 10 µL of 0.1M DTT, and 2.5 
µL of 2 mg/mL boiled ssDNA 
3) Add 300 ng of plasmid DNA 
4) Incubate at 45°C for 30 minutes 
5) Plate on selective media (I used SD-Leu) and allow growth for 2-3 days at 30°C 
Mycophenolic Acid and Canavanine Sensitivity Tests 
Three days beforehand, streak out the strains you wish to use on selective media and 
allow growth for 2-3 days at 30°C.  Grow 2 mL cultures from the colonies in SD-Leu or 
appropriate selective media at 30°C the day before this test is performed, and proceed to 
the following steps: 
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1) Cultures must have OD600  between 0.6-0.8 
2) Add 80 µL of water added to columns 1-8 on a 96-well plate (or as many samples 
as you have) and down four rows (for dilutions) 
3) Using calculated value from dilution series Excel sheet, dilute to OD600 0.1 in row 
1 
4) Do serial 1:5 dilutions starting with row 1 of each column 
5) Plate 5 µL of each dilution (rows 1-5 for each sample) onto appropriate media and 
allow growth for 2-3 days at 30°C 
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